You are here

Daiichi Sankyo

Astellas maintains lead over Daiichi Sankyo with CHMP okay for Xospata

Pharmaforum

Sun, 09/22/19 - 11:02 pm

Astellas' AML drug wins over CHMP — strengthening lead on Daiichi Sankyo

Endpoints

Fri, 09/20/19 - 10:40 pm

Daiichi Sankyo to cut 69 opioid sales jobs

Beckers Hospital Review

Tue, 08/13/19 - 10:26 am

Daiichi Sankyo scores landmark FDA OK for rare tumor drug — albeit with restrictions

Endpoints

Mon, 08/5/19 - 11:32 am

tenosynovial giant cell tumors

FDA declines to approve Daiichi Sankyo's blood cancer treatment

Reuters

Fri, 06/21/19 - 11:55 pm

acute myeloid leukemia

5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit

Motley Fool

Wed, 06/12/19 - 09:45 am

Vertex Pharmaceuticals

tezacaftor/ivacaftor

trastuzumab deruxtecan

Daiichi Sankyo Denies Report That It's Selling Over-the-Counter Drug Unit

BioSpace

Fri, 05/24/19 - 10:40 am

Daiichi Sankyo in talks over OTC unit sale – reports

Pharmaforum

Thu, 05/23/19 - 09:56 am

Daiichi Sankyo comes up way short of promised avian flu vaccine production

Fierce Pharma

Wed, 05/22/19 - 08:34 pm

Daiichi Sankyo Takes Two Products to FDA Advisory Panel; Gets One Yes, One No

BioSpace

Wed, 05/15/19 - 11:42 am

acute myeloid leukemia

FDA questions credibility of Daiichi data ahead of AdComm

Fierce Biotech

Mon, 05/13/19 - 09:32 am

acute myeloid leukemia

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Yahoo/Benzinga

Sat, 05/11/19 - 12:31 pm

The Medicines Company

AstraZeneca's share dilution gamble on Daiichi drug pays off

Biopharma Dive

Thu, 05/9/19 - 10:49 am

trastuzumab deruxtecan

metastatic breast cancer

AZ and Daiichi to file new breast cancer drug after trial success

Pharmaforum

Wed, 05/8/19 - 10:05 am

trastuzumab deruxtecan

antibody-drug conjugate

Daiichi picks immuno-oncology bispecific, triggering payout to Zymeworks

Fierce Biotech

Thu, 04/25/19 - 11:45 am

immuno-oncology

bispecific antibodies

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal

Yahoo/Reuters

Fri, 03/29/19 - 10:06 am

trastuzumab deruxtecan

Doubling down on R&D, Daiichi makes executive changes across its U.S. research unit

Fierce Biotech

Fri, 02/22/19 - 11:46 am

Daiichi gets speedy FDA review for rare cancer drug

Pharmaforum

Fri, 02/8/19 - 09:38 am

priority review

Daiichi Sankyo takes option on diabetes stem cell start-up

Pharmaforum

Sat, 01/12/19 - 11:30 am

Tokyo Institute of Technology

type 1 diabetes

OiDE BetaRevive

Daiichi Sankyo lines up a $900M deal for rights to a cholesterol drug looking to disrupt a blockbuster market

Endpoints

Fri, 01/4/19 - 09:20 am

Esperion Therapeutics

Pages